Physician profile
John Proctor
NPI 1407376239
$3,961.31
in general payments reported to CMS, 2019-2025
42 companies · $1,496 in 2025
The $1,496 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $343 · 2021: $603 · 2022: $286 · 2023: $298 · 2024: $936 · 2025: $1,496.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,730.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,729.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $829.90 | 2021-2025 | |
| Novo Nordisk INC | $638.13 | 2020-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $282.51 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $188.41 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $149.84 | 2024-2025 | Rexulti |
| Amgen INC. | $141.99 | 2020-2025 | Otezla, Repatha, Repatha |
| Glaxosmithkline, LLC. | $141.99 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.64 | 2021-2025 | Jardiance, Tradjenta, Synjardy |
| Xeris Pharmaceuticals, INC. | $104.33 | 2021-2024 | Gvoke Hypopen |
| Abbott Laboratories | $103.20 | 2021-2024 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $99.15 | 2024-2025 | Xifaxan |
| Lundbeck LLC | $85.86 | 2025 | Rexulti |
| Astellas Pharma US INC | $80.76 | 2021-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $76.87 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $67.38 | 2020-2024 | Capvaxive, Gardasil, Gardasil 9 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $64.82 | 2020-2024 | Nexletol |
| Amarin Pharma, INC. | $57.96 | 2021 | |
| Exact Sciences Corporation | $53.21 | 2024-2025 | Cologuard Collection Kit |
| Vanda Pharmaceuticals INC. | $49.36 | 2023-2024 | Hetlioz, Fanapt |
| Sanofi-Aventis U.S. LLC | $47.52 | 2021-2025 | |
| Antares Pharma, INC. | $46.16 | 2025 | Xyosted |
| E.R. Squibb & Sons, L.L.C. | $45.46 | 2024-2025 | Eliquis, Camzyos |
| Scpharmaceuticals INC. | $44.24 | 2024-2025 | |
| Astrazeneca Pharmaceuticals Lp | $38.92 | 2020-2024 | Airsupra |
| Corcept Therapeutics | $36.02 | 2025 | Korlym |
| Beta Bionics, INC. | $32.34 | 2024 | Ilet Bionic Pancreas |
| Alk-Abello, INC | $30.84 | 2025 | Grastek, Ragwitek, Odactra |
| Dexcom, INC. | $28.98 | 2021-2024 | Dexcom G6 Transmitter |
| Almatica Pharma LLC | $28.36 | 2024 | Loreev Xr, Teriparatide |
| Sumitomo Pharma America, INC. | $28.33 | 2024 | Gemtesa |
| Janssen Pharmaceuticals, INC | $25.69 | 2020-2021 | |
| Axsome Therapeutics, INC. | $22.17 | 2025 | Symbravo |
| Takeda Pharmaceuticals U.S.A., INC. | $19.88 | 2021 | |
| Dynavax Technologies Corporation | $19.74 | 2025 | Heplisav-B |
| Daiichi Sankyo INC. | $19.41 | 2024 | Injectafer |
| Sanofi Pasteur INC. | $19.26 | 2023 | |
| Nestle Healthcare Nutrition INC. | $18.62 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.84 | 2025 | Caplyta |
| Shield Therapeutics INC | $14.65 | 2025 | |
| Agile Therapeutics, INC. | $14.61 | 2021 | |
| Gilead Sciences, INC. | $12.46 | 2020 | |
| Allergan, INC. | $11.50 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Proctor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.